Elizabeth J Hait1, Antonia M Calafat2, Russ Hauser3. 1. Division of Gastroenterology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA. 2. National Center for Environmental Health, Centers for Disease Control and Prevention, Boston, MA, USA. 3. Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA ; The Fertility Center, Vincent Memorial Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Phthalates, a family of compounds used in a variety of consumer products, are reproductive and developmental toxicants in experimental animals. One of these phthalates, dibutyl phthalate (DBP), is an inactive ingredient in the coating of Asacol. AIM: To determine if men with inflammatory bowel disease taking Asacol have higher urinary concentrations of monobutyl phthalate (MBP), a metabolite of DBP, compared to the general population in the United States. METHODS: Five patients at the Massachusetts General Hospital Crohn's and Colitis Center, taking at least 800 mg of Asacol three times a day, provided one spot urine sample. Urinary MBP and other phthalate metabolite concentrations were measured by using online solid phase extraction coupled with isotope dilution high-performance liquid chromatography tandem mass spectrometry. RESULTS: In four of the five men, the urinary concentrations of MBP (9888 ng/mL, 12,308 ng/mL, 10,124 ng/mL, and 41,590 ng/mL) and of a minor DBP metabolite, mono(3-carboxypropyl) phthalate (MCPP, 116.4 ng/mL, 163.4 ng/mL 72.6 ng/mL, 5604 ng/mL) were orders of magnitude higher than the background concentrations among the US general population. One subject missed his morning Asacol dose and had urinary MBP concentrations (17.5 ng/mL) similar to background levels. CONCLUSION: We confirmed that men with inflammatory bowel disease taking Asacol have urinary concentrations of MBP and MCPP much higher than background levels.
BACKGROUND:Phthalates, a family of compounds used in a variety of consumer products, are reproductive and developmental toxicants in experimental animals. One of these phthalates, dibutyl phthalate (DBP), is an inactive ingredient in the coating of Asacol. AIM: To determine if men with inflammatory bowel disease taking Asacol have higher urinary concentrations of monobutyl phthalate (MBP), a metabolite of DBP, compared to the general population in the United States. METHODS: Five patients at the Massachusetts General Hospital Crohn's and Colitis Center, taking at least 800 mg of Asacol three times a day, provided one spot urine sample. Urinary MBP and other phthalate metabolite concentrations were measured by using online solid phase extraction coupled with isotope dilution high-performance liquid chromatography tandem mass spectrometry. RESULTS: In four of the five men, the urinary concentrations of MBP (9888 ng/mL, 12,308 ng/mL, 10,124 ng/mL, and 41,590 ng/mL) and of a minor DBP metabolite, mono(3-carboxypropyl) phthalate (MCPP, 116.4 ng/mL, 163.4 ng/mL 72.6 ng/mL, 5604 ng/mL) were orders of magnitude higher than the background concentrations among the US general population. One subject missed his morning Asacol dose and had urinary MBP concentrations (17.5 ng/mL) similar to background levels. CONCLUSION: We confirmed that men with inflammatory bowel disease taking Asacol have urinary concentrations of MBP and MCPP much higher than background levels.
Authors: M C Di Paolo; O A Paoluzi; R Pica; F Iacopini; P Crispino; M Rivera; G Spera; P Paoluzi Journal: Dig Liver Dis Date: 2001-10 Impact factor: 4.088
Authors: Antonia M Calafat; Manori J Silva; John A Reidy; L Earl Gray; Ella Samandar; James L Preau; Arnetra R Herbert; Larry L Needham Journal: J Toxicol Environ Health A Date: 2006-02
Authors: Susan M Duty; Manori J Silva; Dana B Barr; John W Brock; Louise Ryan; Zuying Chen; Robert F Herrick; David C Christiani; Russ Hauser Journal: Epidemiology Date: 2003-05 Impact factor: 4.822
Authors: Manori J Silva; Dana B Barr; John A Reidy; Nicole A Malek; Carolyn C Hodge; Samuel P Caudill; John W Brock; Larry L Needham; Antonia M Calafat Journal: Environ Health Perspect Date: 2004-03 Impact factor: 9.031
Authors: Shanna H Swan; Katharina M Main; Fan Liu; Sara L Stewart; Robin L Kruse; Antonia M Calafat; Catherine S Mao; J Bruce Redmon; Christine L Ternand; Shannon Sullivan; J Lynn Teague Journal: Environ Health Perspect Date: 2005-08 Impact factor: 9.031
Authors: Rebecca A Clewell; Jeremy A Leonard; Chantel I Nicolas; Jerry L Campbell; Miyoung Yoon; Alina Y Efremenko; Patrick D McMullen; Melvin E Andersen; Harvey J Clewell; Katherine A Phillips; Yu-Mei Tan Journal: Toxicol In Vitro Date: 2020-04-08 Impact factor: 3.500
Authors: Feiby L Nassan; Tim I M Korevaar; Brent A Coull; Niels E Skakkebæk; Stephen A Krawetz; Molly Estill; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Ralph A De Poortere; Maarten A Broeren; Alan C Moss; Thomas R Zoeller; Russ Hauser Journal: Int J Hyg Environ Health Date: 2018-08-28 Impact factor: 5.840
Authors: Feiby L Nassan; Brent A Coull; Niels E Skakkebaek; Michelle A Williams; Ramace Dadd; Lidia Mínguez-Alarcón; Stephen A Krawetz; Elizabeth J Hait; Joshua R Korzenik; Alan C Moss; Jennifer B Ford; Russ Hauser Journal: Environ Int Date: 2016-08-26 Impact factor: 9.621
Authors: Feiby L Nassan; Brent A Coull; Niels E Skakkebaek; Anna-Maria Andersson; Michelle A Williams; Lidia Mínguez-Alarcón; Stephen A Krawetz; Janet E Hall; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Alan C Moss; Russ Hauser Journal: Environ Res Date: 2017-10-01 Impact factor: 6.498
Authors: Liselott Källsten; Radwa Almamoun; Paula Pierozan; Erik Nylander; Kalliroi Sdougkou; Jonathan W Martin; Oskar Karlsson Journal: Int J Mol Sci Date: 2022-08-05 Impact factor: 6.208